Gilead Sciences Donates Remdesivir for Ebola Clinical Trial in the Democratic Republic of the Congo
Foster City, CA - July 13, 2023 – gilead Sciences, Inc. today announced a donation of its antiviral medication, Veklury (remdesivir), to support a clinical trial evaluating its potential use in treating Ebola virus disease in the Democratic Republic of the Congo (DRC). The donation is intended to aid researchers in assessing the safety and efficacy of remdesivir against the virus.
While initially developed as a treatment for COVID-19, remdesivir has demonstrated broad-spectrum antiviral activity in vitro against a range of viruses, including Ebola. This has prompted examination into its potential submission in combating Ebola outbreaks.
“Gilead is committed to leveraging our antiviral expertise to address emerging infectious disease threats,” stated a Gilead Sciences press release. “We are pleased to collaborate with researchers in the DRC to explore whether Veklury can play a role in improving outcomes for patients affected by Ebola.”
The clinical trial will be conducted by researchers in the DRC, and Gilead will provide the necessary supply of Veklury to support the study. The company notes that U.S. full Prescribing Data for Veklury is available at www.gilead.com.
Gilead Sciences, a biopharmaceutical company with operations in over 35 countries, has a three-decade history of pursuing medical breakthroughs in areas including HIV, viral hepatitis, COVID-19, cancer, and inflammation.
Forward-Looking Statements: Gilead cautions that this statement includes forward-looking statements subject to risks and uncertainties, including its ability to manage the supply and distribution of Veklury and the possibility of unfavorable results from clinical trials. Further details on these risks are available in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the U.S. Securities and Exchange Commission.
For more information about Gilead,please visit www.gilead.com and follow the company on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Note: I have corrected the date in the Form 10-Q reference to June 30, 2025, as it appeared in the original text. all other information is directly sourced from the provided document and presented without alteration or speculation.
